Angiogenesis: Vascular remodeling of the extracellular matrix involves metalloproteinases

Current Opinion in Hematology

Volumn 10, Issue 2, 2003, Pages 136-141

  Heissig, Beate ^a   Hattori, Koichi ^a,c   Friedrich, Matthias ^a   Rafii, Shahin ^a   Werb, Zena ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CHEMOKINE; CYTOKINE; GELATINASE B; GROWTH FACTOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; RECEPTOR;

ANGIOGENESIS; BASEMENT MEMBRANE; BLOOD VESSEL; BONE MARROW SUPPRESSION; CELL FATE; CELL INVASION; DEGRADATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ANALYSIS; EXTRACELLULAR MATRIX; MICROENVIRONMENT; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; STEM CELL; STROMA; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; BLOOD VESSELS; CYTOKINES; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 0037370649     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200303000-00007     Document Type: Review

References (57)

1. Conway EM, Collen D, Carmeliet P: Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001, 49:507-521. • Review covering various aspects of blood vessel growth.
2. Lyden D, Hattori K, Dias S, et al.: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells brocks tumor angiogenesis and growth. Nat Med 2001, 7:1194-1201. • Demonstrates the significance of mobilization and incorporation of CEPs and hematopoietic cells in supporting tumor angiogenesis in lymphomas and Lewis lung carcinomas. Transplantation and engraftment of wild-type bone marrow into tumor-resistant Id-mutant mice results in restoration of tumor angiogenesis and growth. These studies demonstrate that comobilization of VEGFR1 + CEPs and VEGFR2+ hematopoietic cells are essential for tumor angiogenesis. The primary angiogenic defect in Id-mutant mice is the impaired capacity of CEPs and hematopoietic cells to mobilize and incorporate into tumor vasculature.
3. Pepper MS: Manipulating angiogenesis: from basic science to the bedside. Arterioscler Thromb Vasc Biol 1997, 17:605-619.
4. Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999, 103:1237-1241. • Review on MMPs in angiogenesis including topics like the differential activation of MMPs in two-dimensional versus three-dimensional collagen gels, and the link between MMPs and integrins.
5. Nelson AR, Fingleton B, Rothenberg ML, et al.: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000, 18:1135-1149.
6. Egeblad M, Werb Z: New roles for the matrix metalloproteinases in the progression of cancer. Nat Rev Cancer 2002, 2:163-176. •• A detailed review on the role of MMPs during cancer progression, and an update on clinical studies using MMP inhibitors in anticancer therapy.
7. Lozonschi L, Sunamura M, Kobari M, et al.: Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 1999, 59:1252-1258.
8. Valente P, Fassina G, Melchiori A, et al.: TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998, 75:246-253.
9. Baker AH, Edwards DR, Murphy G: Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002, 115:3719-3727.
10. Folkman J: Seminars in medicine of the Beth Israel Hospital, Boston: clinical applications of research on angiogenesis. N Engl J Med 1995, 333:1757-1763.
11. Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 1998, 49:407-424.
12. Chang C, Werb Z: The many faces of metalloproteases: growth signaling, invasion, angiogenesis, and metastasis. Trends Cell Biol 2001, 11:S37-S43.
13. Nguyen M, Arkell J, Jackson CJ: Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001, 33:960-970. Review on the roles of MMP-2 and MMP-9 in various aspects of angiogenesis.
14. Haas TL, Madri JA: Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: imprications for angiogenesis. Trends Cardiovasc Med 1999, 9:70-77.
15. Itoh T, Tanioka M, Yoshida H, et al.: Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998, 58:1048-1051. • Various tumor cell lines injected intradermally into gelatinase A (MMP-2)-deficient mice decreased the tumor cell growth by 39% for B16-BL6 meranoma and by 240% for Lewis lung carcinoma as compared with controls. As detected by a dorsal air sac assay, tumor-induced angiogenesis was significantly impaired in these mice.
16. Vu TH, Shipley JM, Bergers G, et al.: MMP-9/gelatinase B is a key regurator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422. •• Shows that in MMP-9-deficient mice, skeletal growth plate vascularization is abnormal. Angiogenic activity of explants of hypertrophic cartilage was shown in MMP-9 wild-type animals, but not in the MMP-9 knockout mice, indicating that MMP-9 is necessary to generate angiogenic activators or to inactivate angiogenic inhibitors.
17. Holmbeck K, Bianco P, Caterina J, et al.: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99:81-92.
18. Zhou Z, Apte SS, Soininen R, et al.: Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A 2000, 97:4052-4057.
19. Katori H, Baba Y, Imagawa Y, et al.: Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck. Cancer Lett 2002, 178:151-159.
20. Zhu WH, Guo X, Villaschi S, et al.: Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis. Lab Invest 2000, 80:545-555.
21. Koivunen E, Arap W, Valtanen H, et al.: Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999, 17:768-774. • Describes a peptide inhibitor that specifically inhibits gelatin-binding MMPs, but not other MMPs.
22. Fang J, Shing Y, Wiederschain D, et al.: Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 2000, 97:3884-3889.
23. Marneros AG, Olsen BR: The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol 2001, 20:337-345.
24. Pepper MS: Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001, 21:1104-1117.
25. Ortega N, Werb Z: New functional roles for non-collagenous domains of basement membrane collagens. J Cell Sci 2002, 115:4201-4214.
26. O'Reilly MS, Boehm T, Shing Y, et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
27. O'Reilly MS, Holmgren L, Shing Y, et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
28. Maeshima Y, Sudhakar A, Lively JC, et al.: Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002, 295:140-143. • Shows that tumstatin, after binding to the integrin ανβ33, is an endotheliar cell-specific inhibitor of protein synthesis through inhibition of cap-dependent protein synthesis.
29. Dong Z, Kumar R, Yang X, et al.: Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997, 88:801-810.
30. O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, et al.: Reguration of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999, 274:29568-29571.
31. Ferreras M, Felbor U, Lenhard T, et al.: Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000, 486:247-251.
32. Bein K, Simons M: Thrombospondin type 1 repeats interact with matrix metalloproteinase 2: regulation of metalloproteinase activity. J Biol Chem 2000, 275:32167-32173.
33. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, et al.: Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci U S A 2001, 98:12485-12490.
34. Seandel M, Noack-Kunnmann K, Zhu D, et al.: Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. Blood 2001, 97:2323-2332.
35. Petitclerc E, Boutaud A, Prestayko A, et al.: New functions for non-collagenous domains of human collagen type IV: novel integrin rigands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 2000, 275:8051-8061.
36. Rehn M, Veikkola T, Kukk-Valdre E, et al.: Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 2001, 98:1024-1029.
37. Xu J, Rodriguez D, Petitclerc E, et al.: Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001, 154:1069-1079. •• Shows that a cryptic site within collagen type IV that is exposed after proteinase cleavage promotes angiogenesis and tumor growth, probably by interacting with ανβ3 integrin. This cryptic site is detected in blood vessels from tumors but not normal tissue.
38. Hangai M, Kitaya N, Xu J, et al.: Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before refinal angiogenesis. Am J Pathol 2002, 161:1429-1437.
39. Vu TH, Werb Z: Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000, 14:2123-2133.
40. Bergers G, Brekken R, McMahon G, et al.: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744. •• Matrix metalloproteinase-9 controls tumor angiogenesis by increasing the bioavailability of VEGF, and is expressed by stromal cells but not by cancer cells. MMP-2 also influences tumor growth but not angiogenesis.
41. Engsig MT, Chen QJ, Vu TH, et al.: Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 2000, 151:879-890.
42. Joukov V, Sorsa T, Kumar V, et al.: Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 1997, 16:3898-3911.
43. D'Haese A, Wuyts A, Dillen C, et al.: In vivo neutrophil recruitment by granulocyte chemotactic protein-2 is assisted by gelatinase B/MMP-9 in the mouse. J Interferon Cytokine Res 2000, 20:667-674.
44. Neufeld G, Cohen T, Gengrinovitch S, et al.: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
45. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257. •• Review highlighting the importance of angiogenesis in cancer, hematologic malignancies, and nonneoplastic diseases.
46. Carmeliet P, Ferreira V, Breier G, et al.: Abnormal blood vessel development and lethality in embryos racking a single VEGF allele. Nature 1996, 380:435-439.
47. Ferrara N, Carver-Moore K, Chen H, et al.: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
48. Fong GH, Rossant J, Gertsenstein M, et al.: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376:66-70.
49. Shalaby F, Rossant J, Yamaguchi TP, et al.: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376:62-66.
50. Hattori K, Dias S, Heissig B, et al.: Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001, 193:1005-1014.
51. Heissig B, Hattori K, Dias S, et al.: Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002, 109:625-637. •• Shows the mechanism by which bone marrow-derived stem and progenitor cells are recruited from the bone marrow microenvironment and mobilize to peripheral circulation. Physiologic stressors, including bone marrow suppression or elevation of angiogenic factors, induce MMP-9, resulting in the release of soluble Kit ligand, driving proliferation and mobilization of stem and progenitor cells.
52. Hattori K, Heissig B, Wu Y, et al.: Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1 (+) stem cells from bone-marrow micro-environment. Nat Med 2002, 8:841-849. • Defines the mechanism by which angiogenic factors, including PIGF and VEGF, recruit hematopoietic cells from the bone marrow to the circulation. VEGFR1 is expressed on hematopoietic stem and progenitor cells and conveys signals that promote motility and MMP-9-mediated release of soluble Kit ligand, thereby directing mobilization of these cells to the peripheral circulation.
53. Cho NK, Keyes L, Johnson E, et al.: Developmental control of blood cell migration by the Drosophila VEGF pathway. Cell 2002, 108:865-876.
54. Gerber HP, Malik AK, Solar GP, et al.: VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002, 417:954-958.
55. Eriksson U, Alitalo K: VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies. Nat Med 2002, 8:775-777.
56. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
57. Bergers G, Javaherian K, Lo KM, et al.: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999, 284:808-812.